CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2019--
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that Jill C. Milne, Ph.D.,
Chief Executive Officer, will present a corporate overview at
Oppenheimer’s 29th Annual Healthcare Conference on March 20,
2019 at 8:00am ET at the Westin New York Grand Central Hotel in New York
A webcast of the presentation will be available in the Investors section
of the Company’s website, www.catabasis.com,
and will be archived for 30 days following the presentation.
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy. The global
Phase 3 PolarisDMD trial is currently enrolling boys affected by
Duchenne. For more information on edasalonexent and our Phase 3 trial,
please visit www.catabasis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005120/en/
Source: Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.